Pfizer buys Swiss vaccines
Pfizer executes commercial license agreements for novel human vaccines based on the Swiss company Cytos Biotechnology's Immunodrug technology.
These vaccines incorporate specific disease targets, which are outside the scope of Cytos
Biotechnology’s own research and development programs, and Cytos Biotechnology retains its rights to develop and manufacture vaccines against different disease targets in the same human diseases.
The event triggers payments to Cytos Biotechnology for the execution of the commercial license agreements, and Pfizer acquires world-wide exclusive rights to develop, manufacture and commercialize the specified vaccines.
